KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Expenses (2017 - 2025)

Teva Pharmaceutical Industries' Operating Expenses history spans 9 years, with the latest figure at $634.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 15.48% year-over-year to $634.0 million, compared with a TTM value of $2.3 billion through Dec 2025, up 6.53%, and an annual FY2025 reading of $2.3 billion, up 6.53% over the prior year.
  • Operating Expenses for Q4 2025 was $634.0 million at Teva Pharmaceutical Industries, up from $573.0 million in the prior quarter.
  • The five-year high for Operating Expenses was $634.0 million in Q4 2025, with the low at $458.0 million in Q3 2022.
  • Average Operating Expenses over 5 years is $533.1 million, with a median of $534.0 million recorded in 2023.
  • Year-over-year, Operating Expenses dropped 15.97% in 2021 and then grew 15.48% in 2025.
  • Tracing TEVA's Operating Expenses over 5 years: stood at $521.0 million in 2021, then dropped by 4.41% to $498.0 million in 2022, then grew by 4.22% to $519.0 million in 2023, then increased by 5.78% to $549.0 million in 2024, then increased by 15.48% to $634.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Operating Expenses are $634.0 million (Q4 2025), $573.0 million (Q3 2025), and $549.0 million (Q2 2025).